rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP
A Multicentre Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
Sponsor: Anhui Medical University
Listed as NCT01734044, this PHASE3 trial focuses on Idiopathic Thrombocytopenic Purpura and Purpura and remains completed. Sponsored by Anhui Medical University, it has been updated 5 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Anhui Medical University
- China Medical University, China
- Shandong Provincial Hospital
- Shandong University
- Shenzhen Second People's Hospital
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
- The First Affiliated Hospital of Dalian Medical University
- Zhejiang Provincial Hospital of TCM
For direct contact, visit the study record on ClinicalTrials.gov .